FZD3 and breast cancer: This effect might be mediated by repression of its already known osteogenesis‐relevant targets Runx2 (Deng et al., 2013a, 2013b), Osterix (Baglio et al., 2013), and SATB2 (Deng et al., 2013a, 2013b), to which we here add FZD3 mRNA, a validated target of miR‐31 in the field of breast cancer metastasis (Valastyan et al., 2009) and a member of the noncanonical Wnt signaling pathway (Lee et al., 2008).